Author:
Han Xue,Liu Jingchuan,Hu Xiaoyue,Wang Wei,Wang Qing
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmaceutical Science,Agronomy and Crop Science,Ecology,Aquatic Science,General Medicine,Ecology, Evolution, Behavior and Systematics
Reference35 articles.
1. Bachurin SO, Bovina EV, Ustyugov AA. Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends. MED RES REV. 2017;37(5):1186–225.
2. BLESA R, BALLARD C, ORGOGOZO J, LANE R, THOMAS SK. Caregiver preference for rivastigmine patches versus capsules for the treatment of alzheimer disease, vol. 69. Hagerstown, MD: Lippincott Williams & Wilkins; 2007. p. S23–8.
3. Lefèvre G, Callegari F, Gsteiger S, Xiong Y. Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer’s Disease. DRUG AGING. 2016;33(10):725–36.
4. Zhang D, Wang W, Hou T, Pang Y, Wang C, Wu S, Wang Q. New Delivery Route of Gambogic Acid Via Skin for Topical Targeted Therapy of Cutaneous Melanoma and Reduction of Systemic Toxicity. J PHARM SCI-US. 2021;110(5):2167–76.
5. Ita KB. Transdermal drug delivery: progress and challenges. J DRUG DELIV SCI TEC. 2014;24(3):245–50.